Freshly Printed - allow 10 days lead
Couldn't load pickup availability
Personalized Immunosuppression in Transplantation
Role of Biomarker Monitoring and Therapeutic Drug Monitoring
In-depth coverage of managing immunosuppressant therapy in transplant patients with the goal of maximum benefit from drug therapy and minimal risk of drug toxicity
Michael Oellerich (Edited by), Amitava Dasgupta (Edited by)
9780128008850, Elsevier Science
Hardback, published 20 October 2015
316 pages
23.4 x 19 x 2.4 cm, 0.88 kg
Personalized Immunosuppression in Transplantation: Role of Biomarker Monitoring and Therapeutic Drug Monitoring provides coverage of the various approaches to monitoring immunosuppressants in transplant patients, including the most recently developed biomarker monitoring methods, pharmacogenomics approaches, and traditional therapeutic drug monitoring. The book is written for pathologists, toxicologists, and transplant surgeons who are involved in the management of transplant patients, offering them in-depth coverage of the management of immunosuppressant therapy in transplant patients with the goal of maximum benefit from drug therapy and minimal risk of drug toxicity. This book also provides practical guidelines for managing immunosuppressant therapy, including the therapeutic ranges of various immunosuppressants, the pitfalls of methodologies used for determination of these immunosuppressants in whole blood or plasma, appropriate pharmacogenomics testing for organ transplant recipients, and when biomarker monitoring could be helpful.
Chapter 1. Overview of the pharmacology and toxicology of immunosuppressant agents that require therapeutic drug monitoring Chapter 2. Limitations of Immunoassays Used for Therapeutic Drug Monitoring of Immunosuppressants Chapter 3. Application of liquid chromatography combined with mass spectrometry or tandem mass spectrometry for therapeutic drug monitoring of immunosuppressants Chapter 4. Monitoring Free Mycophenolic Acid Concentration: Is There any Clinical Advantage? Chapter 5. Pharmacogenomics aspect of immunosuppressant therapy Chapter 6. Biomarker monitoring in immunosuppressant therapy: An overview Chapter 7. Graft-derived cell-free DNA as a Marker of Graft Integrity after Transplantation Chapter 8. Biomarkers of tolerance in kidney transplantation Chapter 9. Intracellular concentrations of immunosuppressants Chapter 10. Markers of lymphocyte activation and proliferation Chapter 11. Monitoring Calcineurin inhibitors response based on NFAT-regulated gene expression
